Medicenna TherapeuticsMDNA 
1.90%24h
Medicenna Therapeutics (MDNA) Stock Overview
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
MDNA Stock Information
Medicenna Therapeutics (MDNA) Price Chart
Medicenna Therapeutics Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $1.59 | N/A |
| Market Cap | $103.03M | N/A |
| Shares Outstanding | 64.74M | 19.25% |
| Employees | 16.00 | N/A |
| Shareholder Equity | 29.49M | 41.52% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -9.95 | N/A |
| P/B Ratio | 3.49 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.2522 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$7.44M | N/A |
| EPS | -0.16 | N/A |
| Earnings Yield | -0.1005 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $26.98M | N/A |
| Cash on Hand | $24.87M | N/A |
| Debt to Equity | 0.1747 | 87.64% |
| Current Ratio | $9.57 | 7.29% |
